Nootropics Survey Results And Analysis

Reports a 2014 survey of the online nootropics community (162 respondents, 28 substances rated 0-10). The clever methodological core: uses substances known to be inert or slow-acting (choline bitartrate, short-term bacopa) to estimate a placebo baseline (~3.7-4), so anything at/below ~4 is probably placebo. Findings: only caffeine and modafinil/-afinils clearly beat placebo; most exotic nootropics sit barely above the placebo line with huge variance ('everyone has a unique biochemistry' vs 'everyone has a unique ability to extract patterns from noise'); dose-response is mostly undetectable (the tortured vitamin-D subgroup hunt); BBB-crossing choline forms rate higher. Honest about the data's severe limitations.

Quality 63 · Strong. 63 — low Strong. A useful, data-driven survey with a genuinely clever placebo-baseline trick and instructive data-hygiene/skepticism, but in-the-weeds and landing on a deflationary 'mostly placebo' conclusion. Firm low-Strong.

Claude’s paradigm shift 45 · Moderate. 45 — Moderate. The placebo-baseline-via-known-inert-substance move is a mildly clever methodological contribution; the survey itself isn't novel.

Real-world impact 2 · Minor. 2 — minor/within-blog. Some influence on how the nootropics niche thinks about placebo; no broader reach.